Vertex Pharmaceuticals Incorporated (VRTX): Price and Financial Metrics


Vertex Pharmaceuticals Incorporated (VRTX)

Today's Latest Price: $230.15 USD

12.91 (5.94%)

Updated Mar 30 1:25pm

Add VRTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 337 in Biotech

See all "A" rated Strong Buy stocks

VRTX Stock Summary

  • VRTX has a market capitalization of $57,850,601,156 -- more than approximately 97.71% of US stocks.
  • Price to trailing twelve month operating cash flow for VRTX is currently 36.86, higher than 93.73% of US stocks with positive operating cash flow.
  • With a price/sales ratio of 13.9, Vertex Pharmaceuticals Inc has a higher such ratio than 93.45% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Vertex Pharmaceuticals Inc, a group of peers worth examining would be QCOM, AMAT, REGN, MU, and AMD.
  • Visit VRTX's SEC page to see the company's official filings. To visit the company's web site, go to www.vrtx.com.
VRTX Daily Price Range
VRTX 52-Week Price Range

VRTX Stock Price Chart More Charts


VRTX Price/Volume Stats

Current price $230.15 52-week high $249.85
Prev. close $217.24 52-week low $163.68
Day low $220.00 Volume 870,083
Day high $233.77 Avg. volume 1,805,990
50-day MA $229.60 Dividend yield N/A
200-day MA $201.13 Market Cap 59.67B

Vertex Pharmaceuticals Incorporated (VRTX) Company Bio


Vertex Pharmaceuticals engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. The company was founded in 1989 and is based in Boston, Massachusetts.

VRTX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$230.15$31889.5114579%

Below please find a table outlining a discounted cash flow forecast for VRTX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Vertex Pharmaceuticals Inc ranked in the 97th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 14651.17%; returns of such proportions should be viewed with some skepticism, though. In terms of the factors that were most noteworthy in this DCF analysis for VRTX, they are:

  • In the past 3.29 years, Vertex Pharmaceuticals Inc has a compound free cash flow growth rate of 2.66%; that's higher than 96.84% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than merely 5.32% of the free cash flow producing stocks we're observing.
  • VRTX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 61.83% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%14292%
1%14435%
2%14579%
3%14723%
4%14867%
5%15011%

Want more companies with a valuation profile/forecast similar to that of Vertex Pharmaceuticals Inc? See NVCR, DRRX, ASRT, RDY, and FVE.


VRTX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

VRTX Latest Social Stream


Loading social stream, please wait...

View Full VRTX Social Stream

VRTX Price Returns

1-mo 2.73%
3-mo 5.12%
6-mo 38.05%
1-year 25.12%
3-year 110.47%
5-year 97.67%
YTD 5.12%
2019 32.13%
2018 10.58%
2017 103.42%
2016 -41.45%
2015 5.92%

Continue Researching VRTX

Want to see what other sources are saying about Vertex Pharmaceuticals Inc's financials and stock price? Try the links below:

Vertex Pharmaceuticals Inc (VRTX) Stock Price | Nasdaq
Vertex Pharmaceuticals Inc (VRTX) Stock Quote, History and News - Yahoo Finance
Vertex Pharmaceuticals Inc (VRTX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8663 seconds.